Microbes mediated immunogenic cell death in cancer immunotherapy

IF 7.5 2区 医学 Q1 IMMUNOLOGY Immunological Reviews Pub Date : 2023-08-08 DOI:10.1111/imr.13261
Jumin Huang, Fugang Duan, Chun Xie, Jiahui Xu, Yizhong Zhang, Yuwei Wang, Yu-Ping Tang, Elaine Lai-Han Leung
{"title":"Microbes mediated immunogenic cell death in cancer immunotherapy","authors":"Jumin Huang,&nbsp;Fugang Duan,&nbsp;Chun Xie,&nbsp;Jiahui Xu,&nbsp;Yizhong Zhang,&nbsp;Yuwei Wang,&nbsp;Yu-Ping Tang,&nbsp;Elaine Lai-Han Leung","doi":"10.1111/imr.13261","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Immunogenic cell death (ICD) is one of the 12 distinct cell death forms, which can trigger immune system to fight against cancer cells. During ICD, a number of cellular changes occur that can stimulate an immune response, including the release of molecules called damage-associated molecular patterns (DAMPs), signaling to immune cells to recognize and attack cancer cells. By virtue of their pivotal role in immune surveillance, ICD-based drug development has been a new approach to explore novel therapeutic combinations and personalized strategies in cancer therapy. Several small molecules and microbes can induce ICD-relevant signals and cause cancer cell death. In this review, we highlighted the role of microbe-mediate ICD in cancer immunotherapy and described the mechanisms through which microbes might serve as ICD inducers in cancer treatment. We also discussed current attempts to combine microbes with chemotherapy regimens or immune checkpoint inhibitors (ICIs) in the treatment of cancer patients. We surmise that manipulation of microbes may guide personalized therapeutic interventions to facilitate anticancer immune response.</p>\n </div>","PeriodicalId":178,"journal":{"name":"Immunological Reviews","volume":"321 1","pages":"128-142"},"PeriodicalIF":7.5000,"publicationDate":"2023-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunological Reviews","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/imr.13261","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Immunogenic cell death (ICD) is one of the 12 distinct cell death forms, which can trigger immune system to fight against cancer cells. During ICD, a number of cellular changes occur that can stimulate an immune response, including the release of molecules called damage-associated molecular patterns (DAMPs), signaling to immune cells to recognize and attack cancer cells. By virtue of their pivotal role in immune surveillance, ICD-based drug development has been a new approach to explore novel therapeutic combinations and personalized strategies in cancer therapy. Several small molecules and microbes can induce ICD-relevant signals and cause cancer cell death. In this review, we highlighted the role of microbe-mediate ICD in cancer immunotherapy and described the mechanisms through which microbes might serve as ICD inducers in cancer treatment. We also discussed current attempts to combine microbes with chemotherapy regimens or immune checkpoint inhibitors (ICIs) in the treatment of cancer patients. We surmise that manipulation of microbes may guide personalized therapeutic interventions to facilitate anticancer immune response.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
癌症免疫疗法中微生物介导的免疫细胞死亡。
免疫原性细胞死亡(ICD)是12种不同的细胞死亡形式之一,可触发免疫系统对抗癌细胞。在免疫原性细胞死亡过程中,细胞会发生一系列变化,从而激发免疫反应,包括释放称为损伤相关分子模式(DAMPs)的分子,向免疫细胞发出识别和攻击癌细胞的信号。由于它们在免疫监视中的关键作用,基于 ICD 的药物开发已成为探索癌症治疗中新型治疗组合和个性化策略的新方法。一些小分子和微生物可诱导 ICD 相关信号并导致癌细胞死亡。在这篇综述中,我们强调了微生物介导的 ICD 在癌症免疫疗法中的作用,并描述了微生物在癌症治疗中作为 ICD 诱导剂的机制。我们还讨论了目前将微生物与化疗方案或免疫检查点抑制剂(ICIs)结合起来治疗癌症患者的尝试。我们推测,操纵微生物可指导个性化治疗干预,促进抗癌免疫反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Immunological Reviews
Immunological Reviews 医学-免疫学
CiteScore
16.20
自引率
1.10%
发文量
118
审稿时长
4-8 weeks
期刊介绍: Immunological Reviews is a specialized journal that focuses on various aspects of immunological research. It encompasses a wide range of topics, such as clinical immunology, experimental immunology, and investigations related to allergy and the immune system. The journal follows a unique approach where each volume is dedicated solely to a specific area of immunological research. However, collectively, these volumes aim to offer an extensive and up-to-date overview of the latest advancements in basic immunology and their practical implications in clinical settings.
期刊最新文献
Issue Information Introduction Lessons Learned From Clinical Trials of Immunotherapeutics for COVID-19. Balanced regulation of ROS production and inflammasome activation in preventing early development of colorectal cancer. Role of inflammasomes and neuroinflammation in epilepsy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1